Table 3. First-line studies with bevacizumab in MPM patients.
| Author (reference) | Chemotherapy regimen | Phase | Status | N | RR/DCR | mPFS | mOS |
|---|---|---|---|---|---|---|---|
|
Kindler et al (2012) |
Cis/gemcitabine |
II Ra |
Completed |
53b,c |
25%/76% |
6.9 mo |
15.6 mo |
|
Dowell et al (2012) |
Cis/pemetrexed |
II |
Completed |
52d |
40%/75% |
6.9 mo |
14.8 mo |
|
Zalcman et al (2012) |
Cis/pemetrexed |
II–III R |
Phase II completed |
47b |
38%/57%e |
NR |
NR |
| Present study | Carbo/pemetrexed | II | Completed | 76 | 34%/92% | 6.9 mo | 15.3 mo |
Abbreviations: Carbo=carboplatin; Cis=cisplatin; DCR=disease control rate; mo=months; mOS=median overall survival; mPFS=median progression-free survival; MPM=malignant pleural mesothelioma; N=number of evaluable patients; NR=not reported; R=randomised; RR=response rate.
a
Double-blind, placebo-controlled trial.
b
Only patients in the bevacizumab arm were reported.
c
Included four patients (7.5%) with peritoneal mesothelioma in the bevacizumab arm.
d
Included eight patients (15%) with mesothelioma of peritoneum and tunica vaginalis.
e
Assessed at 6 months after starting the treatment.